Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) rose 7.9% during trading on Tuesday. The stock traded as high as $32.25 and last traded at $33.0390. Approximately 1,339 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 99,621 shares. The stock had previously closed at $30.63.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on NBTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Guggenheim began coverage on Nanobiotix in a report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.67.
Check Out Our Latest Report on NBTX
Nanobiotix Price Performance
The company’s 50 day moving average is $31.00 and its 200 day moving average is $33.99.
Nanobiotix Company Profile
Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy.
Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.
Featured Stories
- Five stocks we like better than Nanobiotix
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
